RxDoctor Payments Data

David Fabi, MD

Adult Reconstructive Orthopaedic Surgery · San Diego, CANPI 1326240805

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 71.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $137,123 and has fallen 99.6% since, to $538 in 2025.

$251,758in general payments, 2019–2025

Across 297 payments — averaging $847.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$180K
  • Microport Orthopedics Inc$28K
  • Encore Medical, LP$26K
  • Vertex$8K
  • DJO, LLC$2K
  • Stryker$2K
  • plus $5K from 18 others
$98,490in research payments, 2019–2025

Across 31 payments — averaging $3177.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$52K
  • Microport Orthopedics Inc$46K

What the payments were for

  • Consulting fees$70,78228%
  • Speaking & faculty fees$125,68950%
  • Travel & lodging$48,35819%
  • Food & beverage$6,9293%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$251,758 in reported general payments places this provider in the 85th percentile of 136 adult reconstructive orthopaedic surgery providers in California.

See all adult reconstructive orthopaedic surgery providers in California

Medicare billing

Part B allowed, 2024
$489,553
Medicare patients
518
Services billed
8,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$17,053
Celecoxib157$3,850
Gabapentin159$1,191
Doxycycline Hyclate158$964
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$431
Amoxicillin99$149
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$103
Meloxicam33$69
Methylprednisolone13$60
Clindamycin Hcl13$32

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →